| Balance Sheets | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | 8,289,108 | 7,820,608 | 10,709,937 | |
| Prepaid expenses and other current assets | 284,200 | 537,044 | 275,223 | |
| Total current assets | 8,573,308 | 8,357,652 | 10,985,160 | |
| Property and equipment, net | 399,077 | 35,741 | 40,559 | |
| Other assets | 28,775 | 29,882 | 30,988 | |
| Total assets | 9,001,160 | 8,423,275 | 11,056,707 | |
| Accounts payable | 1,326,782 | 936,030 | 940,586 | |
| Accrued expenses and other current liabilities | 215,697 | 244,456 | 859,442 | |
| Deferred revenue | 2,997,952 | 3,225,581 | 3,225,581 | |
| Notes payable | - | - | 0 | |
| Due to related party | 139,823 | 139,823 | 139,823 | |
| Other current liability | - | - | 2,306 | |
| Total current liabilities | 4,680,254 | 4,545,890 | 5,167,738 | |
| Total liabilities | 4,680,254 | 4,545,890 | 5,167,738 | |
| Common stock, 0.0001 par value100,000,000 shares authorized 531,968 and 531,968 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively | 53 | 53 | 53 | |
| Additional paid-in capital | 103,361,379 | 100,544,058 | 100,331,014 | |
| Accumulated deficit | -99,040,526 | -96,666,726 | -94,442,098 | |
| Total stockholders' equity | 4,320,906 | 3,877,385 | 5,888,969 | |
| Total liabilities and stockholders' (deficit) equity | 9,001,160 | 8,423,275 | 11,056,707 | |
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)